Dana Investment Advisors Inc. Sells 3,057 Shares of AbbVie Inc. $ABBV

Posted by Stanley Muller on May 16th, 2026

Dana Investment Advisors Inc. decreased its position in AbbVie Inc. (NYSE:ABBV – Free Report) by 2.0% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 147,506 shares of the company’s stock after selling 3,057 shares during the quarter. AbbVie accounts for 1.0% of Dana Investment Advisors Inc.’s portfolio, making the stock its 16th biggest holding. Dana Investment Advisors Inc.’s holdings in AbbVie were worth $33,704,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in ABBV. Eclectic Associates Inc. ADV increased its position in shares of AbbVie by 0.8% during the 4th quarter. Eclectic Associates Inc. ADV now owns 5,852 shares of the company’s stock valued at $1,337,000 after purchasing an additional 45 shares during the last quarter. Weil Company Inc. increased its position in shares of AbbVie by 2.3% during the 3rd quarter. Weil Company Inc. now owns 2,026 shares of the company’s stock valued at $469,000 after purchasing an additional 46 shares during the last quarter. Hardin Capital Partners LLC increased its position in shares of AbbVie by 1.4% during the 4th quarter. Hardin Capital Partners LLC now owns 3,321 shares of the company’s stock valued at $759,000 after purchasing an additional 46 shares during the last quarter. Dogwood Wealth Management LLC increased its position in shares of AbbVie by 10.8% during the 4th quarter. Dogwood Wealth Management LLC now owns 473 shares of the company’s stock valued at $108,000 after purchasing an additional 46 shares during the last quarter. Finally, Inlet Private Wealth LLC increased its position in shares of AbbVie by 0.3% during the 3rd quarter. Inlet Private Wealth LLC now owns 17,001 shares of the company’s stock valued at $3,937,000 after purchasing an additional 47 shares during the last quarter. Institutional investors own 70.23% of the company’s stock.

Insider Buying and Selling at AbbVie

In other AbbVie news, SVP David Ryan Purdue sold 5,230 shares of the company’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the completion of the sale, the senior vice president directly owned 2,654 shares in the company, valued at approximately $619,868.24. This represents a 66.34% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Perry C. Siatis sold 22,381 shares of the company’s stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the sale, the executive vice president owned 38,137 shares of the company’s stock, valued at $8,771,510. This represents a 36.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Corporate insiders own 0.06% of the company’s stock.

Analyst Upgrades and Downgrades

ABBV has been the topic of several analyst reports. Sanford C. Bernstein reissued a “market perform” rating on shares of AbbVie in a research report on Thursday, February 5th. Piper Sandler boosted their target price on AbbVie from $294.00 to $298.00 and gave the company an “overweight” rating in a research report on Thursday. Morgan Stanley boosted their target price on AbbVie from $270.00 to $278.00 and gave the company an “overweight” rating in a research report on Thursday, April 30th. Cantor Fitzgerald reissued an “overweight” rating and set a $240.00 target price on shares of AbbVie in a research report on Thursday, April 30th. Finally, UBS Group cut their target price on AbbVie from $240.00 to $230.00 and set a “neutral” rating on the stock in a research report on Thursday, February 5th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $253.43.

Check Out Our Latest Stock Analysis on AbbVie

More AbbVie News

Here are the key news stories impacting AbbVie this week:

Positive Sentiment: AbbVie’s Q1 results were supported by strong sales of Skyrizi and Rinvoq, which helped offset ongoing Humira declines and boosted the company’s 2026 guidance. Article: How Important Are Skyrizi and Rinvoq to AbbVie’s Q1 Results?
Positive Sentiment: Analysts have turned more optimistic on AbbVie’s earnings power, with Erste Group raising FY2027 EPS estimates and the company’s long-term pipeline still viewed favorably. Article: AbbVie analyst estimate update
Positive Sentiment: Recent commentary highlighted AbbVie as a potentially better growth story than AstraZeneca because of its valuation, dividend profile, and pipeline strength. Article: Which Pharma Giant Offers Better Growth: AstraZeneca or AbbVie?

AbbVie Stock Down 0.1%

Shares of AbbVie stock opened at $210.54 on Friday. The stock’s fifty day moving average is $210.27 and its two-hundred day moving average is $220.10. The company has a market capitalization of $371.97 billion, a PE ratio of 103.71, a price-to-earnings-growth ratio of 0.73 and a beta of 0.32. AbbVie Inc. has a 52 week low of $180.25 and a 52 week high of $244.81.

AbbVie (NYSE:ABBV – Get Free Report) last announced its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, beating the consensus estimate of $2.59 by $0.06. The company had revenue of $15 billion for the quarter, compared to the consensus estimate of $14.72 billion. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.AbbVie’s quarterly revenue was up 12.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.46 EPS. As a group, research analysts anticipate that AbbVie Inc. will post 14.32 earnings per share for the current year.

AbbVie Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th were given a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 3.3%. The ex-dividend date of this dividend was Wednesday, April 15th. AbbVie’s dividend payout ratio is 340.89%.

AbbVie Profile

(Free Report)

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.